| Name | Title | Contact Details |
|---|
NDRI National Disease Research Interchange is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.
At Fox Chase Cancer Center, defeating cancer is our calling. Fox Chase is one of the nation`s first dedicated cancer hospitals, and our researchers and physicians have made major contributions to scientific advancement since our establishment more than a century ago in 1904. Fox Chase scientists have made breakthroughs in cancer prevention, diagnosis, treatment, and survivorship, and have earned the highest awards in their fields, including two Nobel Prizes. We translate these pioneering discoveries into world-class clinical care every day - with a single purpose: to defeat cancer and help the people it impacts. This calling is rooted in our cancer-specific, multidisciplinary teams of doctors, researchers, practitioners, and five-time Magnet designated nurses, who are all more than specialists in cancer; they are international experts in distinct types of cancer, whose deep and focused expertise provides the best chance for the best outcome anywhere along the cancer continuum. And they`re helping to advance the way cancer treatment is delivered around the world. The way we work together, with this single, shared passion for our patients` well-being, is what makes us truly unique.
axialHealthcare offers an evidence-driven, predictive solution that limits opioid misuse and optimizes care for patients with pain or opioid use disorder.
Healthcare Partners Investments is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.